

## **December 2014 Appendix 4C**

### **Melbourne, Australia, 30 January 2015**

Prescient Therapeutics Limited ("**Prescient**" or "**the Company**") provides the following Appendix 4C in relation to the quarter ended 31 December 2014.

During the quarter, the Company completed the acquisition of AKTivate Therapeutics Pty Ltd ("AKTivate") following approval received at the Company's 2014 Annual General Meeting of shareholders which was held on 28 November 2014.

AKTivate's technology inhibits the highly promising drug target AKT and includes two active clinical trials – a Phase 1b/2 in breast cancer and an active Phase 1b/2 in ovarian cancer. These trials are funded by US government authorities including grants from the Department of Defense and National Cancer Institute.

Under the terms of the AKTivate agreement Prescient paid US\$300,000 cash consideration as well as 6.7 million shares (post-consolidation). A further 5 million shares will be paid on reaching clearly defined clinical success milestones.

### **Corporate**

During the quarter, the Company completed a share consolidation on a 20 : 1 basis and changed its name to Prescient Therapeutics Limited from Virax Holdings Limited.

Cash at the end of the quarter, as detailed in the attached Appendix 4C, was approximately \$2.3 million following the one-off cash payment for the AKTivate acquisition.

**Ends.**





**About Prescient Therapeutics**

Prescient Therapeutics is a clinical stage oncology company currently engaged in the development of novel products for the treatment of cancer. It holds an exclusive worldwide license to the novel cancer compound PTX-100 (GGTI-2418) for the treatment of multiple myeloma, breast and pancreatic cancer. PTX-100 is expected to enter Phase 1b/2 clinical trials in multiple myeloma and breast cancer in 2015.

Prescient Therapeutics has acquired oncology company AKTivate and its novel PTX-200 (TCN-P) cancer drug. The company's technology inhibits the highly promising drug target AKT and includes two active clinical trials – a Phase 1b/2 in breast cancer and an active Phase 1b in ovarian cancer. These trials are funded by US government authorities including grants from the Department of Defence and National Cancer Institute.

In addition, the company has granted a license to major French biotechnology company Transgene for access to its Co-X-Gene™ technology for use in two of Transgene's immunotherapeutic products.

**Contact:**

**Mr Sean Henbury**

Company Secretary

Ph: +61 (0) 3 9620 3333



# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005, 17/12/2010

Name of entity

Prescient Therapeutics Limited (Formerly Virax Holdings Limited)

ABN

56 006 569 106

Quarter ended ("current quarter")

31 December 2014

### Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (6 months) \$A'000
1.1 Receipts from customers	-	-
1.2 Payments for:		
(a) staff costs	(90)	(132)
(b) advertising and marketing	(51)	(51)
(c) research and development	(68)	(394)
(d) leased assets	-	-
(e) other working capital	(351)	(565)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	15	30
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other items		
(a) Net GST (paid to)/recovered from ATO	-	-
(b) R & D tax rebate received	-	-
(c) Government grant received	-	-
(d) R&D contract contributions received	-	-
<b>Net operating cash flows</b>	<b>(545)</b>	<b>(1,112)</b>

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

	Current quarter \$A'000	Year to date (6 months) \$A'000
1.8 Net operating cash flows (carried forward)	(545)	(1,112)
<b>Cash flows related to investing activities</b>		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	(365)	(365)
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:	-	-
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
<b>Net investing cash flows</b>	<b>(365)</b>	<b>(365)</b>
<b>1.14 Total operating and investing cash flows</b>	<b>(910)</b>	<b>(1,477)</b>
<b>Cash flows related to financing activities</b>		
1.15 Proceeds from issues of shares, options, etc.	-	-
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Capital raising costs	-	-
<b>Net financing cash flows</b>	<b>-</b>	<b>-</b>
<b>Net increase (decrease) in cash held</b>	<b>(910)</b>	<b>(1,477)</b>
1.21 Cash at beginning of quarter/year to date	3,219	3,786
Exchange rate adjustments to item 1.20	-	-
1.23 <b>Cash at end of quarter</b>	<b>2,309</b>	<b>2,309</b>

+ See chapter 19 for defined terms.

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	46
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Director's fees and salaries paid to directors during the December 2014 quarter.
--

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

Issue of 6,700,005 shares for the acquisition of Aktivite Therapeutics Pty Ltd.
---

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

-
---

**Financing facilities available**

*Add notes as necessary for an understanding of the position.*

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

---

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	2,309	3,220
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
<b>Total: cash at end of quarter</b> (item 1.23)	2,309	3,220


**Acquisitions and disposals of business entities**

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	AKTivate Therapeutics Pty Ltd	-
5.2 Place of incorporation or registration	Australia	-
5.3 Consideration for acquisition or disposal	USD \$300,000 cash and 6,700,005 shares in Prescient therapeutics	-
5.4 Total net assets	-	-
5.5 Nature of business	Biotech company	-

**Compliance statement**

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:

  
 \_\_\_\_\_  
 (Company Secretary)

Date: 30 January 2015

Print name: Sean Henbury

---

+ See chapter 19 for defined terms.

## Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirement requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

---

+ See chapter 19 for defined terms.